BMJ Open Glycosylated haemoglobin for screening and diagnosis of gestational diabetes mellitus

Alhossain Khalafallah,1,2,3 Eileen Phuah,4 Abdul Majeed Al-Barazan,2 Irena Nikakis,4 Andrea Radford,5 Wade Clarkson,5 Clinton Trevett,5 Terry Brain,5 Val Gebski,6 Anne Corbould1,2

ABSTRACT

Objectives: The oral glucose tolerance test (OGTT) is a cumbersome test that is time consuming, labour intensive and often poorly tolerated by pregnant women. To date, glycosylated haemoglobin (HbA1c) is the most accepted measure of chronic glycaemia outside of pregnancy. HbA1c is an uncomplicated test, less time consuming, does not require any specific patient preparation and is considered straightforward compared with the OGTT. Therefore, we prospectively tested the utility of the HbA1c when used as a screening tool in pregnancy for gestational diabetes mellitus (GDM).

Settings: Primary health care. Single tertiary referral centre, Tasmania, Australia.

Participants: A direct comparison between HbA1c levels and the OGTT results in pregnant women, tested concurrently at the 24–28 gestational week, was undertaken. A full profile of 480 pregnant women during the period from September 2012 to July 2014 was completed. Median and mean age of participants was 29 years (range 18–47 years).

Interventions: A simultaneous prospective assessment of HbA1c versus standard OGTT in a cohort of consecutive pregnant women presenting to our institute was performed.

Results: The number of women who had GDM according to OGTT criteria was 57, representing 11.9% of the evaluated 480 pregnant women. Using a cut-off value for HbA1c at 5.1% (32 mmol/mol) for detecting GDM showed sensitivity of 61% and specificity of 68% with negative predictive value (NPV) of 93%, versus sensitivity of 27% and specificity of 95% with NPV of 91% when using HbA1c cut-off value of 5.4% (36 mmol/mol).

Conclusions: Our results suggest that pregnant women with an HbA1c of ≥5.4% (36 mmol/mol) should proceed with an OGTT. This may result in a significant reduction in the burden of testing on both patients and testing facility staff and resources. Further investigations are required to integrate and optimise the HbA1c as a single, non-fasting, screening tool for GDM.

Trial registration number: ACTRN12611000739910.

Strengths and limitations of this study

- Oral glucose tolerance test is a standard screening test for gestational diabetes mellitus (GDM); however, it requires fasting overnight and three separate blood tests over 2 h, is often poorly tolerated by pregnant women and is labour intensive, adding an additional burden to an overstretched health system.
- Glycosylated haemoglobin (HbA1c) is a simple, single, non-fasting test that may give insight to gestational diabetes.
- Our study of 480 pregnant women suggests that HbA1c could be a useful screening tool for GDM.
- The diagnosis of GDM would be missed in few patients by using HbA1c as a screening tool.
- The major effect on HbA1c is usually seen in the last 4–8 weeks of red cell age. Thus, it should be interpreted with caution if detecting a new diagnosis of GDM.

INTRODUCTION

Pregnancies affected by gestational diabetes mellitus (GDM) are at risk of developing a number of serious obstetric complications such as fetal growth abnormalities, shoulder dystocia, birth injury, prematurity and increased Caesarean section rate, as well as having long-term implications for the well-being of mother and infant.1 The risk of adverse perinatal and maternal outcomes is directly proportional to the degree of hyperglycaemia, with a linear relationship between maternal glucose and various neonatal outcomes.1–3

The current screening process using the revised Australasian Diabetes in Pregnancy Society (ADIPS) guidelines published in 2013 based on the International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria has resulted in an increase in the detected incidence of GDM in the
Australian population from 6–8% to 13%. The guidelines recommend a 75 g oral glucose tolerance test (OGTT) at 24–28 weeks gestation for all pregnant women.

However, the OGTT is a cumbersome test that is time consuming, labour intensive and often poorly tolerated by pregnant women. The patient must be fasted, sit for over 2 h and have at least three venipunctures. The gravida is prone to nausea and vomiting from delayed gastric emptying. This, coupled with gestational oedema compromising venous access, can lead to an invalid test result. Furthermore, the recommendation for universal screening has significantly increased the burden of testing.

The instability of blood glucose ex vivo leads to significant interlaboratory variation of results. It is thought to vary by up to 14% in a third of cases.

While guidelines are in place, the glucose threshold values for diagnosis and methods of testing for GDM vary greatly from one institution to another. Moreover, as it is a specialised test, many collection centres do not provide this service, particularly in rural and remote locations, potentially disadvantaging an already vulnerable cohort of women.

The need for a simpler, more universally acceptable and accessible test is becoming increasingly apparent. Glycosylated haemoglobin (HbA1c) is currently the most accepted measure of chronic glycaemia outside of pregnancy.

The National Health and Medical Research Council (NHMRC) guidelines 2009 recommend HbA1c to be the basis for diagnosis of type 2 diabetes mellitus, with a value of 48 mmol/mol or 6.5% or greater being confirmatory.

HbA1c is the product of an irreversible non-enzymatic binding of glucose to plasma proteins, specifically haemoglobin (Hb). The mean plasma glucose over the erythrocyte life span is correlated with a degree of glycosylation. It is a single, non-fasting blood test and reflects glucose levels over the previous 4–8 weeks. As compared with glucose testing, it has been shown to have greater reliability with <6% interlaboratory variation. Thus, HbA1c test has improved analytical stability with greater standardisation between assays and less preanalytical variation. Further comparisons with fasting blood glucose and 2 h postprandial glucose have shown HbA1c to have less intraindividual variation as it does not appear to be affected by diurnal variation, meals, fasting, acute stress or by the large number of common drugs known to influence glucose metabolism. The test is validated for a red cell survival time of approximately 3 months. Therefore, results need to be interpreted carefully in the clinical situation whereby erythrocyte half-life is significantly shortened by, for example, haemoglobinopathies, haemolysis, transfusion, anaemia and chronic renal failure.

Dilutional anaemia of pregnancy and increased erythrocyte turnover have, to date, hampered its acceptance as a tool for screening, if not diagnosis, of GDM.

The accuracy of HbA1c as a screening test in pregnancy has been extensively studied over the past three decades and results have been inconsistent. Many of these studies were conducted prior to the Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) findings on which the current IADPSG 2010 and ADIPS screening strategies are based. Consequently, there is significant heterogeneity in both methods used for screening for GDM and diagnostic glucose thresholds when compared with HbA1c. In addition, and importantly, many studies have used the same reference range for HbA1c in both pregnant and non-pregnant patients. Nonetheless, the results of these studies have been inconclusive. The overlap of HbA1c values between normal and GDM-affected pregnancies has always been too great for HbA1c to have sufficient sensitivity and specificity to meet the screening requirements of a test.

Using current screening guidelines, Nielsen et al have shown the normal upper range of HbA1c in early pregnancy to be significantly lower than levels found outside of pregnancy (5.7%/39 mmol/mol) and did not significantly differ from late pregnancy (5.6%/38 mmol/mol). This study looked at non-GDM women at 14 and 33 weeks gestation as determined by negative OGTT values. Hb levels, however, were not accounted for and anaemia could have inadvertently lowered results.

O’Connor et al did find trimester-specific reference intervals for HbA1c in a study of 246 non-diabetic pregnant women with normal Hb levels: the first trimester range was 4.8–5.5% (29–37 mmol/mol), second trimester 4.4–5.4% (25–36 mmol/mol) and third trimester 4.4–5.4% (25–36 mmol/mol).

A meta-analysis of 43 studies, involving over 2812 patients with GDM in China compared with 5918 controls concluded that, based on the summary receiver operating characteristic (ROC) curve analysis, HbA1c is a useful diagnostic tool for confirming GDM. Studies from 2001 to 2012 were included in this meta-analysis with varying diagnostic criteria for GDM and cut-off values for HbA1c, such that the authors recommended HbA1c to be tested in parallel with conventional tests.

Our current study is focusing on parallel prospective comparison between the HbA1c and standard OGTT when used as a screening tool in pregnancy for GDM.

Objectives of the study

The aim of the study was to provide an objective assessment of the utility of HbA1c when used as a screening tool in pregnancy. A direct comparison of HbA1c levels with results of the OGTT in women, tested concurrently at the 24–28 gestational week, was undertaken.

PATIENTS AND METHODS

Participants

We recruited 480 pregnant women during the period from September 2012 to July 2014. For these patients,
we performed a simultaneous prospective assessment of HbA1c versus standard OGTT in a cohort of consecutive pregnant women presenting to the Launceston General Hospital (LGH; a tertiary referral teaching hospital in Tasmania, Australia). Pregnant women were approached when attending their routine third trimester OGTT test at our institution. Written informed consent was obtained from all participants. For these patients, simultaneous full blood count (FBC) and iron studies were performed as per our routine antenatal assessment. Median and mean age of participants was identical 29 years (range 18–47).

The trial was registered in the Australian New Zealand Clinical Trials Registry (http://www.anzctr.org.au/ACTRN12611000739910) and the WHO Clinical Trials Registry (http://www.who.int/trialsearch/Trial2.aspx?trialid=ACTRN12611000739910).

Inclusion criteria
All sequential pregnant women who were ≥18 years old and presented for OGTT test at 24–28 weeks gestation in our tertiary referral hospital were offered the trial. The OGTT was performed according to our policy at the LGH at the time of study.

Exclusion criteria
Twin pregnancies were excluded as well as women with an early diagnosis of GDM, that is, prior to 24 weeks gestation as this may create unknown bias to the results of the trial.

Parameters such as gravity, parity, ethnicity, personal and family history of diabetes, type of delivery, complications of pregnancy, body mass index and perinatal data, as well as data regarding the infants’ APGAR scores, weight and sex were collected prospectively from women enrolled in the trial after informed consent.

OGTT was performed according to our standard protocol. The patient was required to have been in good health and to be consuming a normal diet, particularly with regard to carbohydrate intake (>150 g/day). The test was performed after an overnight fast of 10 h. The test was started before 10:00 and the patient remained resting quietly for the duration of the OGTT. Blood samples were collected into Becton Dickinson 2 mL Fluoride Oxalate Vacutainer tubes. A sample was collected at baseline and then the patient consumed the 75 g glucose load. We used a commercially available product containing 75 g of dextrose in 300 mL carbonated liquid (SteriHealth Gluco Scan 75 g). The patient was required to consume the whole volume within 5 min of starting the drink. Further blood samples were collected at 1 and 2 h post-start of the dextrose drink. Glucose was measured within 3 h of collection of the sample using the Abbott glucose hexokinase method on an Architect C8000 analyser (Abbott Australasia Pty Ltd).

HbA1c samples were collected into Becton Dickinson 4 mL K2EDTA Vacutainer tubes. HbA1c was measured by immunoassay using the DCA 2000 (Siemens Ltd, Marburg, Germany). The DCA 2000 analyser measures HbA1c standardised to the National Glycohemoglobin Standardization Program (NGSP), which is in turn aligned to the Diabetes Control and Complications Trial (DCCT) results with international standardisation as set by the International Federation of Clinical Chemistry (IFCC; http://www.ngsp.org/certified.asp).

GDM was defined as present if fasting blood glucose was ≥5.1 mmol/L or glucose tolerance test (GTT) 1 h ≥10.0 mmol/L or GTT 2 h ≥8.5 mmol/L. GDM was defined as not present if fasting blood glucose was <5.1 mmol/L and GTT 1 h <10 mmol/L and GTT 2 h <8.5 mmol/L. The diagnostic criteria are defined by the 2013 ADIPS consensus guidelines for the testing and diagnosis of GDM in Australia.5 19

Statistical analysis
Patient characteristics were expressed as percentages for categorical variables, and as mean and SD, or median with IQR for continuous variables.

Groups were compared using t test, and multiple-category variables were analysed using analysis of variance.

Bland-Altman plot was used to assess the agreement between HbA1c levels and the values of the GTT. ROC curve was performed to assess the discriminative capacity of HbA1c for detection of GDM. Sensitivity, specificity, predictive values, false-positive and false-negative rates were calculated. All analyses were performed with SAS (V9.3).

Results
We recruited 480 women with a median of 26 and mean of 25.7 weeks gestation. Approximately 12% of our cohort were diagnosed with GDM according to the ADIPS criteria, and this is consistent with the expected incidence of GDM in Australia.

The median gestational age at enrolment was 26 weeks with a mean of 25.7 weeks (SD 3.3) with a mean fasting glucose level of 4.37 mmol/L (SD 0.46), 6.85 mmol/L (SD 1.7) at 1 h and 5.84 mmol/L (SD 1.45) at 2 h. The mean HbA1c was 4.8% (29 mmol/mol; SD 0.36). FBC and iron studies were assessed in the same participants, showing median Hb of 119 g/L (range 92–145) and median ferritin of 12 µg/L (range 1–204).

Spearman correlation between OGTT and HbA1c showed significant association of 1 and 2 h OGTT with HbA1c (p≤0.0001; table 1). However, no such correlation existed for Hb and OGTT (p=0.38 and 0.25, respectively). Further analyses demonstrated that ferritin and Hb levels correlated with HbA1c (p=0.02, p≤0.0001, respectively; table 1). Bland-Altman correlations between OGTT and HbA1c are shown in figures 1 and 2.

The number of women in our cohort who had GDM according to the OGTT criteria was 57, representing...
11.9% of the 480 studied pregnant women. Overall, in the same trial period at our laboratory, there were 97 out of 1795 pregnant women (5.4%) tested for OGTT who had a fasting blood glucose level >5.1 mmol/L, while at 2 h, the glucose level was >8.5 mmol/L in 96 out of 1775 patients (5%).

It is worth noting that most of the patients studied (88%) were iron deficient with ferritin level <30 µg/L, while 57% had ferritin <15 µg/L similar to the results of previous trials. The HbA1c distribution by GDM status is shown in figure 3.

Using an arbitrary cut-off value for HbA1c at 5.1% (32 mmol/mol) to detect GDM showed sensitivity of 61% and specificity of 95% with NPV of 91% when using a HbA1c cut-off value of 5.4% (36 mmol/mol; table 2).

Regarding ethnicity, 93% of the population studied were Caucasian, with 4% Asian and 3% Aboriginal. There was no significant correlation between GDM or HbA1c and ethnicity. Nevertheless, this study is not statistically powered to detect such differences as other trials demonstrated.

The sex of the baby, complications of pregnancy or type of delivery did not show an association to HbA1c levels. However, GDM itself was associated with more complications during pregnancy (p<0.0001) compared with non-GDM pregnant women but did not influence intrapartum or postpartum or natal complications (table 3).

### Table 1: Spearman correlations between OGTT and HbA1c

<table>
<thead>
<tr>
<th></th>
<th>Fasting blood glucose</th>
<th>OGTT (mmol/L) 1 h</th>
<th>OGTT (mmol/L) 2 h</th>
<th>HbA1c (%)</th>
<th>Ferritin</th>
<th>Hb</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting blood glucose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OGTT (mmol/L) 1 h</td>
<td>1.00 000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;0.0001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OGTT (mmol/L) 2 h</td>
<td>0.36 109</td>
<td>0.31 745</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>0.34 298</td>
<td>0.21 911</td>
<td>0.22 906</td>
<td>1.00 000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferritin</td>
<td>0.03 316</td>
<td>0.11 589</td>
<td>0.00 636</td>
<td>−0.10 974</td>
<td>1.00 000</td>
<td></td>
</tr>
<tr>
<td>0.4757</td>
<td>0.0129</td>
<td>0.8912</td>
<td>0.0233</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>465</td>
<td>460</td>
<td>465</td>
<td>427</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hb</td>
<td>−0.03 201</td>
<td>0.03 996</td>
<td>−0.05 220</td>
<td>−0.26 569</td>
<td>0.23 075</td>
<td>1.00 000</td>
</tr>
<tr>
<td>0.4860</td>
<td>0.3869</td>
<td>0.2557</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>476</td>
<td>471</td>
<td>476</td>
<td>436</td>
<td>463</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Hb, haemoglobin; HbA1c, glycosylated haemoglobin; OGTT, oral glucose tolerance test.
Proposed cost saving

The use of HbA1c in the context of gestational diabetes screening provides an economy at the point of specimen collection. The resource requirement for the specimen collection facility may be significantly reduced, for example, bleeding a patient once for an HbA1c as opposed to three times for a GTT (baseline, 1 and 2 h). Consumables and equipment, salaries and accommodation are also reduced which may, over time, support an economic argument.

Cost of OGTT and HbA1c

Although a cost analysis was not the primary objective of the study, it is worthwhile attempting to calculate approximate costs of consumables/equipment/accommodation per bleed.

In our laboratory, the cost of reagents and consumables to perform an HbA1c is approximately US$9.00. This is compared with the cost of performing the three glucose tests as part of an OGTT which is in the order of $0.50. This increased cost of laboratory consumables is more than offset by the reduction in labour and infrastructure costs of collecting a single sample for HbA1c compared with performing the OGTT.

At the LGH public laboratory, the laboratory consumable cost per bleed is approximately US$2, and the salary of the nurse performing the venipuncture is approximately $10 per bleed. The cost of testing an additional blood sample is approximately $9 per given episode. It therefore costs $12.00 to perform the single blood collection for an HbA1c and $34 for the OGTT. In addition, the 75 g glucose load for the OGTT costs $2. The overall cost of performing the two procedures is approximately $21 for an HbA1c and $36.50 for an OGTT, a saving of $15.50 per episode for HbA1c compared with OGTT.

Furthermore, in health systems that often have resourcing issues such as staff and accommodation, it is far more efficient to have a patient bled once rather than

Table 2

<table>
<thead>
<tr>
<th>HbA1c (%)</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>PPV</th>
<th>NPV</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>0</td>
<td>0.997</td>
<td>0</td>
<td>0.888</td>
</tr>
<tr>
<td>6.1</td>
<td>0.02</td>
<td>0.997</td>
<td>0.5</td>
<td>0.89</td>
</tr>
<tr>
<td>5.9</td>
<td>0.061</td>
<td>0.997</td>
<td>0.75</td>
<td>0.894</td>
</tr>
<tr>
<td>5.8</td>
<td>0.082</td>
<td>0.997</td>
<td>0.8</td>
<td>0.896</td>
</tr>
<tr>
<td>5.7</td>
<td>0.102</td>
<td>0.995</td>
<td>0.714</td>
<td>0.898</td>
</tr>
<tr>
<td>5.6</td>
<td>0.122</td>
<td>0.99</td>
<td>0.6</td>
<td>0.9</td>
</tr>
<tr>
<td>5.5</td>
<td>0.224</td>
<td>0.982</td>
<td>0.611</td>
<td>0.91</td>
</tr>
<tr>
<td>5.4</td>
<td>0.265</td>
<td>0.954</td>
<td>0.419</td>
<td>0.912</td>
</tr>
<tr>
<td>5.3</td>
<td>0.347</td>
<td>0.884</td>
<td>0.274</td>
<td>0.915</td>
</tr>
<tr>
<td>5.2</td>
<td>0.551</td>
<td>0.797</td>
<td>0.255</td>
<td>0.934</td>
</tr>
<tr>
<td>5.1</td>
<td>0.612</td>
<td>0.676</td>
<td>0.192</td>
<td>0.933</td>
</tr>
<tr>
<td>5</td>
<td>0.694</td>
<td>0.519</td>
<td>0.154</td>
<td>0.931</td>
</tr>
<tr>
<td>4.9</td>
<td>0.735</td>
<td>0.314</td>
<td>0.119</td>
<td>0.904</td>
</tr>
<tr>
<td>4.8</td>
<td>0.816</td>
<td>0.18</td>
<td>0.111</td>
<td>0.886</td>
</tr>
<tr>
<td>4.7</td>
<td>0.959</td>
<td>0.1</td>
<td>0.118</td>
<td>0.951</td>
</tr>
<tr>
<td>4.6</td>
<td>0.959</td>
<td>0.046</td>
<td>0.112</td>
<td>0.9</td>
</tr>
</tbody>
</table>

HbA1c, glycosylated haemoglobin; NPV, negative predictive value; PPV, positive predictive value.

Table 3

<table>
<thead>
<tr>
<th>GDM status (N, %)</th>
<th>Complications during pregnancy</th>
<th>Intrapartum complications</th>
<th>Postpartum complications</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0=No gestational diabetes</td>
<td>1=Gestational diabetes</td>
<td>p Value*</td>
</tr>
<tr>
<td></td>
<td>1=No</td>
<td>2=Yes</td>
<td>3=Insufficient</td>
</tr>
<tr>
<td>Complications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>during pregnancy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1=No</td>
<td>305 (97)</td>
<td>8 (3)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>2=Yes</td>
<td>95 (68)</td>
<td>45 (32)</td>
<td>0.8203</td>
</tr>
<tr>
<td>3=Insufficient</td>
<td>21 (91)</td>
<td>2 (9)</td>
<td></td>
</tr>
<tr>
<td>information</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intrapartum</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1=No</td>
<td>378 (88)</td>
<td>52 (12)</td>
<td>0.9047</td>
</tr>
<tr>
<td>2=Yes</td>
<td>20 (87)</td>
<td>3 (13)</td>
<td></td>
</tr>
<tr>
<td>3=Insufficient</td>
<td>23 (92)</td>
<td>2 (8)</td>
<td></td>
</tr>
<tr>
<td>information</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postpartum</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1=No</td>
<td>362 (88)</td>
<td>50 (12)</td>
<td></td>
</tr>
<tr>
<td>2=Yes</td>
<td>36 (88)</td>
<td>5 (12)</td>
<td></td>
</tr>
<tr>
<td>3=Insufficient</td>
<td>23 (92)</td>
<td>2 (8)</td>
<td></td>
</tr>
<tr>
<td>information</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*p Groups were compared with χ² or Fisher tests.

Table 3 Does gestational diabetes mellitus (GDM) status influence complications during pregnancy, intrapartum and postpartum?

![Figure 3](image-url) Glycosylated haemoglobin (HbA1c) distribution by gestational diabetes mellitus (GDM) status.
three times and accommodate them (and their party) in the waiting room for more than 2 h.

Furthermore, there is an economy for the patients themselves in terms of time off work, parking and issues such as child care when applicable.

DISCUSSION

Since the time of the original publications investigating the value of HbA1c for GDM diagnosis, laboratory testing of HbA1c has become increasingly standardised and evolved to be a simpler, more accurate and automated test. It has developed from simple ELISA to turbidometric inhibition immunoassay, an assay method largely unaffected by either haemoglobinopathies or uraemia, through to precision liquid chromatography. Previously, HbA1c results could not be compared between one laboratory and another let alone one country to another. However, since international standardisation of the assay, this is no longer the case.

Rajput and colleagues 2012 studied 607 women between 24 and 28 weeks’ gestation, similar to our study. They were evaluated for GDM using OGTT based on American Diabetes Association (ADA) criteria (2 h 75 g OGTT or ‘one-step strategy’) and concurrently tested for HbA1c. A cut-off value of ≥ 5.4% (36 mmol/mol) had a sensitivity of 85.7% and specificity of 61.1%. Only 2.8% would have been diagnosed incorrectly as GDM. Further investigations are required to integrate HbA1c as a single, non-fasting diagnostic test for GDM. However, the high NPV may make it useful as an initial screening test. For example, patients with an HbA1c ≥ 5.4% (36 mmol/mol) should proceed with an OGTT. This alone would generate a significant reduction in the burden of testing.

The results of our study indicate that using an HbA1c level of 5.4% (36 mmol/mol) at third trimester (26 weeks) has a specificity of 95%, sensitivity of 27% and NPV of 91% in detecting GDM, in line with the reference range for pregnancy reported by other studies. Using a cut-off value of HbA1c 5.1% (32 mmol/mol), the sensitivity increased to 55%, at the expense of specificity, which decreased to 80%. The positive association between HbA1c and OGTT is an advantage, but the low sensitivity of HbA1c becomes a hurdle in standardising such a test in pregnancy.

Further investigations are required to integrate HbA1c in establishing the diagnosis of GDM. Therefore, further optimisation of the test is required prior to its application as a screening tool for GDM.

The use of HbA1c as a screening tool for gestational diabetes has yet to be evaluated in an Australian population. To our knowledge, there are no published data comparing the 75 g two-step OGTT as per current guidelines with HbA1c in establishing the diagnosis of GDM. It is anticipated that validating the diagnostic utility of HbA1c in pregnancy in Australia would result in a reduction in the burden of testing, increase patient access and compliance, therefore facilitate the management of the gestational diabetic mother and perhaps improve perinatal and maternal outcomes.

We found that the application of HbA1c as a method for screening GDM within the Australian population needs further refining and definition for its use. Outside of pregnancy, it has been established that HbA1c measurement can accelerate and facilitate patient screening, diagnosis and management of diabetes. The usual cut-off value for diagnosing diabetes outside pregnancy seems to be much higher than the cut-off value needed to diagnose diabetes associated with pregnancy. This is in concordance with other studies already detailed.

The results of our study indicate that using an HbA1c value in Asian Indian women ranged between 5.36 ± 0.36% and ≥ 6% (42 mmol/mol) in women with GDM in a study of 507 women. This study was interesting in that all trimesters were studied. Women who had a positive HbA1c but negative OGTT in the first trimester subsequently developed GDM. The implication of this is twofold. First, the HbA1c false positives identified in other studies may have actually been true positives with OGTT results being false negatives. Second, if the results of this study are reproducible, then management instituted earlier may have an impact on outcomes for babies of mothers who, despite being screened, detected and treated during third trimester, still suffer the consequences of GDM.

Genetically determined variations in the degree of glycosylation of Hb, independent of glycaemia, are thought to exist and are reflected in ethnic differences in HbA1c levels. This suggests that population reference ranges need to be established prior to universally implementing HbA1c as a screening test in gestational diabetes. It is worth noting that the vast majority of our studied population were Caucasian (94%).

hormone, corticotropin-releasing hormone, placental lactogen and progesterone, all act to increase insulin resistance in the mother, serving to ensure adequate supply of nutrients to the developing fetus. Where the mother has insufficient pancreatic function to cope with this increasing insulin resistance, diabetes ensues.

In contrast, in type 2 (non-pregnant) DM, increasing insulin resistance obviously is not mediated by a placenta but rather by a complex interplay between genetic predisposition, obesity and decreased physical activity. Abdominal fat is metabolically active, producing hormones that promote insulin resistance. Leptin, tumor necrosis factor-α and resistin are among the many ‘adipokines’ implicated in insulin resistance and subsequent development of type 2 DM. Adipose cells, furthermore, are thought to trigger chronic inflammation, which in turn contributes to the development of insulin resistance.

However, the difference in the performance of HbA1c in non-pregnant versus pregnant populations may not be entirely explained by different pathophysiology.

In summary, employing a cut-off value for HbA1c at 5.4% (36 mmol/mol) for detecting GDM showed NPV of 91% and specificity of 95%. Similar results could be achieved with HbA1c level >5.1% as a screening tool for GDM. The high specificity and NPV value may be useful as an initial screening test for GDM. This may result in significant reduction in the burden of testing on both patients and testing facility, staff and resources. Further investigations are required to integrate HbA1c as a single non-fasting screening tool for GDM with optimisation of the cut-off value.

Author affiliations
1Department of Medicine, Launceston General Hospital, Launceston, Tasmania, Australia
2School of Health Sciences, University of Tasmania, Launceston, Tasmania, Australia
3Menzies Institute for Medical Research, University of Tasmania, Launceston, Tasmania, Australia
4Department of Obstetrics and Gynaecology, Launceston General Hospital and Royal Hobart Hospital, Launceston, Tasmania, Australia
5Pathology Department, Launceston General Hospital, Launceston, Tasmania, Australia
6Australian National Health and Medical Research Council Clinical Trials Centre, Sydney, New South Wales, Australia

Acknowledgements The authors wish to acknowledge and thank Mr David Seaton, Manager of Pathology Department, Launceston General Hospital, Tasmania, Australia, for his kind help, guidance and technical support throughout the research process as well as all staff of the Pathology Department, Launceston General Hospital, for their enormous help in conducting this study. They also thank sincerely Ms Anne-Sophie Veillard and Valerie Gares from the Australian National Health and Medical Research Council Clinical Trials Centre for their kind help in conduction of the statistical analyses. Finally, they wish to thank sincerely Dr Brooke Kirkby and Mr Gerald Bates, Pathology Department, Launceston General Hospital, Tasmania, Australia, for their kind help in reviewing the manuscript.

Contributors AK is the principal investigator of the study who organised and coordinated all aspects of the research including all steps of the manuscript preparation. He is responsible for the study concept, design, writing, reviewing, editing and approving the manuscript in its final form. EP, AMA-B, IN and AR recruited the patients and contributed in the study design, analysis and interpretation of data, writing the manuscript and reviewed and approved the manuscript in its final form. WC, CT, TB, VG and AC conducted the testing, supervised the patients at the Pathology Department, Launceston General Hospital, and drafted and finally approved the manuscript.

Funding This study was supported by the Pathology Department, Launceston General Hospital, Launceston, Tasmania, Australia, in affiliation to the University of Tasmania, Australia. Pathology Department provided logistic and monetary support with no influence in the study design; collection, analysis, and interpretation of data; writing the research report; and the decision to submit the manuscript for publication. This is an investigator-initiated study. All aspects of the study conception, design, administration, data collection, analysis and presentation have been undertaken independently of any sponsor.

Competing interests None declared.

Patient consent Obtained.

Ethics approval The trial was approved by Tasmanian Human Ethics Committee, Australia, as a part of another trial targeting the same population.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES
recommendations on the diagnosis and classification of hyperglycemia in pregnancy. *Diabetes Care* 2010;33:676–82.


Glycosylated haemoglobin for screening and diagnosis of gestational diabetes mellitus

Alhossain Khalafallah, Eileen Phuah, Abdul Majeed Al-Barazan, Irena Nikakis, Andrea Radford, Wade Clarkson, Clinton Trevett, Terry Brain, Val Gebski and Anne Corbould

*BMJ Open* 2016 6:
doi: 10.1136/bmjopen-2016-011059

Updated information and services can be found at:
http://bmjopen.bmj.com/content/6/4/e011059

These include:

**References**
This article cites 30 articles, 6 of which you can access for free at:
http://bmjopen.bmj.com/content/6/4/e011059#BIBL

**Open Access**
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections
- Diabetes and Endocrinology (423)
- Diagnostics (215)
- Evidence based practice (737)
- Health economics (369)
- Obgyn (353)
- Public health (2285)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/